• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Removal From Key Russell Value Indexes Will Impact PACS Group (PACS) Investors

    Simply Wall St·07/08/2026 07:28:29
    Listen to the news
    • In late June 2026, PACS Group, Inc. was removed from several major Russell Value benchmarks, including the Russell 3000 and Russell 2000 Value indexes, prompting index-tracking funds to adjust their holdings.
    • Because these benchmarks are widely used by passive investors, PACS Group’s removal could meaningfully alter who owns the stock and how it trades day to day.
    • We’ll now examine how PACS Group’s removal from multiple Russell Value benchmarks may reshape aspects of its existing investment narrative.

    Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

    PACS Group Investment Narrative Recap

    To own PACS Group, you need to believe in its ability to keep improving margins and occupancy across a rapidly expanded portfolio while maintaining clean governance and controls. Its removal from several Russell Value benchmarks mainly affects who trades the stock, rather than the underlying drivers, so it does not materially change the near term focus on integrating new facilities or the key risk around reimbursement and regulatory scrutiny.

    Against this backdrop, the recently announced US$250 million share repurchase program stands out, as it directly touches how PACS Group responds to shifts in its shareholder base after index removal. For investors watching near term catalysts, the combination of ongoing acquisitions and buybacks keeps attention on execution at new facilities and on how capital is balanced between growth, integration costs, and returning cash to shareholders.

    But while index changes and buybacks draw headlines, investors should also be aware of the ongoing reliance on favorable Medicaid and state reimbursement frameworks...

    Read the full narrative on PACS Group (it's free!)

    PACS Group's narrative projects $6.7 billion revenue and $454.1 million earnings by 2029. This requires 7.1% yearly revenue growth and a roughly $210 million earnings increase from $243.8 million today.

    Uncover how PACS Group's forecasts yield a $49.67 fair value, a 14% upside to its current price.

    Exploring Other Perspectives

    PACS 1-Year Stock Price Chart
    PACS 1-Year Stock Price Chart

    Three Simply Wall St Community fair value estimates for PACS Group range from US$49.67 to US$60.08, underscoring how far apart views can be. As you weigh these opinions, remember that any shift in Medicaid or state reimbursement structures in key markets could have broad implications for PACS Group’s ability to translate its footprint into sustained earnings performance, so it is worth comparing several perspectives before deciding where you stand.

    Explore 3 other fair value estimates on PACS Group - why the stock might be worth just $49.67!

    The Verdict Is Yours

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    No Opportunity In PACS Group?

    Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.